Feng Qian1, Ye Zhong2, Edward L Hannan2. 1. School of Public Health, Room 169, One University Place, Rensselaer, USA. Electronic address: fqian@albany.edu. 2. School of Public Health, Room 169, One University Place, Rensselaer, USA.
Abstract
BACKGROUND: Endeavor zotarolimus-eluting stents (E-ZES) and everolimus-eluting stents (EES) as second-generation stents were approved for use in percutaneous coronary interventions (PCIs) in 2008. We aimed to evaluate the long-term outcomes of E-ZES vs. EES using New York State (NYS) cardiac registries and to compare long-term effectiveness of E-ZES vs. EES in six "off-label" and two "high-risk" subgroups. METHODS: We created a longitudinal database by linking the NYS cardiac registries, the statewide hospital discharge data, the National Death Index, and the U.S. Census file (2010) for patients receiving either E-ZES or EES from July 2008 through December 2010. We examined outcome measures of all-cause mortality, acute myocardial infarction (AMI), target lesion PCI (TLPCI), and target vessel coronary artery bypass graft (TVCABG) surgery for 13,663 propensity score matched pairs in the 6-year follow-up period. We applied Kaplan-Meier methods and Cox proportional hazards regression for further adjustment of propensity-matched pairs. RESULTS: Compared with patients receiving EES, patients receiving E-ZES had a significantly higher rate of 6-year all-cause mortality (adjusted hazard ratio (AHR): 1.10, 95% confidence interval (CI): 1.04-1.17, P=0.003), AMI (AHR: 1.12, 95% CI: 1.02-1.23, P=0.01), TLPCI (AHR: 1.28, 95% CI: 1.18-1.39, P<0.001), and TVCABG (AHR: 1.47, 95% CI: 1.26-1.71, P<0.001). EES had better or similar long-term outcomes than E-ZES for the subgroups that were examined. CONCLUSION: At 6years, patients receiving EES generally had better or comparable mortality, AMI, TLPCI, and TVCABG outcomes compared with patients receiving E-ZES. Published by Elsevier B.V.
BACKGROUND: Endeavor zotarolimus-eluting stents (E-ZES) and everolimus-eluting stents (EES) as second-generation stents were approved for use in percutaneous coronary interventions (PCIs) in 2008. We aimed to evaluate the long-term outcomes of E-ZES vs. EES using New York State (NYS) cardiac registries and to compare long-term effectiveness of E-ZES vs. EES in six "off-label" and two "high-risk" subgroups. METHODS: We created a longitudinal database by linking the NYS cardiac registries, the statewide hospital discharge data, the National Death Index, and the U.S. Census file (2010) for patients receiving either E-ZES or EES from July 2008 through December 2010. We examined outcome measures of all-cause mortality, acute myocardial infarction (AMI), target lesion PCI (TLPCI), and target vessel coronary artery bypass graft (TVCABG) surgery for 13,663 propensity score matched pairs in the 6-year follow-up period. We applied Kaplan-Meier methods and Cox proportional hazards regression for further adjustment of propensity-matched pairs. RESULTS: Compared with patients receiving EES, patients receiving E-ZES had a significantly higher rate of 6-year all-cause mortality (adjusted hazard ratio (AHR): 1.10, 95% confidence interval (CI): 1.04-1.17, P=0.003), AMI (AHR: 1.12, 95% CI: 1.02-1.23, P=0.01), TLPCI (AHR: 1.28, 95% CI: 1.18-1.39, P<0.001), and TVCABG (AHR: 1.47, 95% CI: 1.26-1.71, P<0.001). EES had better or similar long-term outcomes than E-ZES for the subgroups that were examined. CONCLUSION: At 6years, patients receiving EES generally had better or comparable mortality, AMI, TLPCI, and TVCABG outcomes compared with patients receiving E-ZES. Published by Elsevier B.V.
Authors: David E Kandzari; Martin B Leon; Ian Meredith; Jean Fajadet; William Wijns; Laura Mauri Journal: JACC Cardiovasc Interv Date: 2013-04-17 Impact factor: 11.195
Authors: Alfazir Omar; Rebecca Torguson; Hironori Kitabata; Lakshmana K Pendyala; Joshua P Loh; Marco A Magalhaes; Lowell F Satler; William O Suddath; Augusto D Pichard; Ron Waksman Journal: Catheter Cardiovasc Interv Date: 2014-08-05 Impact factor: 2.692
Authors: Martin B Leon; Eugenia Nikolsky; Donald E Cutlip; Laura Mauri; Henry Liberman; Hadley Wilson; John Patterson; Jeffrey Moses; David E Kandzari Journal: JACC Cardiovasc Interv Date: 2010-10 Impact factor: 11.195
Authors: Frederick A Masoudi; Edward P Havranek; Pam Wolfe; Cary P Gross; Saif S Rathore; John F Steiner; Diana L Ordin; Harlan M Krumholz Journal: Am Heart J Date: 2003-08 Impact factor: 4.749
Authors: Pieter C Smits; Georgios J Vlachojannis; Eugene Patrick McFadden; Kees-Jan Royaards; Jochem Wassing; Kaiyum Sheik Joesoef; Carlos van Mieghem; Martin van de Ent Journal: JACC Cardiovasc Interv Date: 2015-07-22 Impact factor: 11.195